Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial
N Jain, JM Reuben, H Kantarjian, C Li… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
J Pinilla-Ibarz, K Cathcart, T Korontsvit… - Blood, The Journal …, 2000 - ashpublications.org
Chronic myelogenous leukemia (CML) presents a unique opportunity to develop therapeutic
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …
A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease
PG Maslak, T Dao, M Gomez, S Chanel, J Packin… - Leukemia, 2008 - nature.com
Previous clinical vaccination trials of BCR-ABL peptides demonstrated that certain amino-
acid sequences crossing the p210 breakpoint were immunogenic in patients with chronic …
acid sequences crossing the p210 breakpoint were immunogenic in patients with chronic …
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - The Lancet, 2005 - thelancet.com
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
K Cathcart, J Pinilla-Ibarz, T Korontsvit, J Schwartz… - Blood, 2004 - ashpublications.org
A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
JM Rojas, K Knight, L Wang, RE Clark - Leukemia, 2007 - nature.com
Peptides from the e14a2 BCR-ABL junction will elicit T-cell responses in vitro. Here, 19
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses
J Pinilla-Ibarz, T Korontsvit, V Zakhaleva… - …, 2005 - haematologica.org
BACKGROUND AND OBJECTIVES: Chronic myelogenous leukemia (CML) presents a
unique opportunity to develop therapeutic strategies using vaccination against a truly tumor …
unique opportunity to develop therapeutic strategies using vaccination against a truly tumor …
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
BD Smith, YL Kasamon, J Kowalski, C Gocke… - Clinical Cancer …, 2010 - AACR
Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …
Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
M Bocchia, M Defina, L Aprile, M Ippoliti… - Nature Reviews …, 2010 - nature.com
Abstract Background. A 63-year-old woman with chronic myeloid leukemia (CML) received
treatment with interferon (IFN)-α for 6 years. After achieving a complete cytogenetic …
treatment with interferon (IFN)-α for 6 years. After achieving a complete cytogenetic …
Peptide vaccines for myeloid leukaemias
T Dao, DA Scheinberg - Best Practice & Research Clinical Haematology, 2008 - Elsevier
The development of cancer vaccines directed against myeloid leukaemias has been a
research area of intense interest in the past decade. Both human studies in vitro and mouse …
research area of intense interest in the past decade. Both human studies in vitro and mouse …
相关搜索
- residual disease leukemia patients
- peptide vaccines myeloid leukaemias
- cml patients minimal disease
- tumor burden leukemia patients
- analog peptides minimal disease
- tumor burden residual disease
- cml patients analog peptides
- imatinib mesylate leukemia patients
- bcr abl minimal disease
- gm csf leukemia patients
- imatinib mesylate residual disease
- gm csf residual disease